Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000777675 | SCV000913594 | likely benign | Hereditary cancer-predisposing syndrome | 2018-01-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001481778 | SCV001686128 | likely benign | Familial cancer of breast | 2021-03-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000777675 | SCV005106997 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-30 | criteria provided, single submitter | clinical testing | The c.645A>G variant (also known as p.A215A), located in coding exon 4 of the CHEK2 gene, results from an A to G substitution at nucleotide position 645. This nucleotide substitution does not change the alanine at codon 215. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |
Myriad Genetics, |
RCV001481778 | SCV005896032 | benign | Familial cancer of breast | 2024-10-03 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |